SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. received a U.S. patent for a proprietary combination of antimicrobials and cannabinoids aimed at enhancing the efficacy of existing antibiotics against resistant bacterial strains [1][2]. Group 1: Patent and Technology - The newly granted U.S. patent complements existing patents in the U.S. and Europe, reinforcing global intellectual property protection for NeuroThera's antimicrobial-potentiating platform [2]. - The patented technology combines established antibiotics with cannabinoids like Δ⁹-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), showing enhanced antimicrobial activity in pre-clinical studies against resistant Gram-positive pathogens such as MRSA [3][5]. - The platform aims to leverage the long-term safety data of these antibiotics to minimize risks while providing an effective and affordable therapeutic solution [3]. Group 2: Market Context and Need - Prolonged antibiotic use has led to the emergence of resistant bacterial strains, with MRSA causing approximately 130,000 deaths worldwide in 2021, a significant increase from 57,000 deaths in 2019 [4]. - The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by the rising challenge of antimicrobial resistance [6]. - The "antimicrobial-sparing" effect of NeuroThera's combination may reduce the need for new antibiotics, addressing serious side effects associated with resistance development and organ toxicity [7]. Group 3: Industry Challenges - Pharmaceutical companies are increasingly reluctant to develop new antibiotics due to long development timelines, high costs, and rapid bacterial resistance, leading to a decline in innovation in this field [8].